Fig. 1: The relationship between RPL10 ufmylation and the development of PAAD.
From: The ufmylation modification of ribosomal protein L10 in the development of pancreatic adenocarcinoma
A The ufmylation of RPL10 by Co-IP and immunoblotting using anti-RPL10 antibody in PANC-1 cells. B The ufmylation of RPL10 by Co-IP and Western blot using anti-UFM1 antibody in PANC-1 cells. C The ufmylation of RPS3 by Co-IP and immunoblotting using anti-RPL10 antibody in PANC-1 cells. D The ufmylation of RPS3 by Co-IP and Western blot using anti-UFM1 antibody in PANC-1 cells. E The hazard ratio of RPL10 and ufmylation related gene expression in PAAD patients (http://gepia2.cancer-pku.cn/#index). The hazards ratios were analyzed by Cox proportional hazard model based on the expressions of the genes in PAAD patient tissues. F Comparison of RPL10 ufmylation level between tumor tissues and adjacent normal tissues of PAAD patients (n = 5). All experiments were independently repeated for 3 times.
